Patient characteristics and treatment
| Characteristic . | Value . |
|---|---|
| No. of patients | 95 |
| CP CML, n (%) | 38 (40) |
| AP CML, n (%) | 11 (11.5) |
| BC CML, n (%) | 35 (37) |
| Myeloid | 18 |
| Lymphoid | 17 |
| Ph+ ALL, n (%) | 11 (11.5) |
| Median age, y (range) | 56 (18-77) |
| Median time from diagnosis, mo (range) | 49 (4-181) |
| Median time on IM, mo (range) | 32 (4-66) |
| Patients positive for Bcr-Abl KD mutations at the time of IM failure, n (%) | 51 (54) |
| Patients who received dasatinib as second TKI, n | 55 |
| Patients who received nilotinib as second TKI, n | 40 |
| Patients who received dasatinib as third TKI, n | 19 |
| Patients who received nilotinib as third TKI, n | 7 |
| Characteristic . | Value . |
|---|---|
| No. of patients | 95 |
| CP CML, n (%) | 38 (40) |
| AP CML, n (%) | 11 (11.5) |
| BC CML, n (%) | 35 (37) |
| Myeloid | 18 |
| Lymphoid | 17 |
| Ph+ ALL, n (%) | 11 (11.5) |
| Median age, y (range) | 56 (18-77) |
| Median time from diagnosis, mo (range) | 49 (4-181) |
| Median time on IM, mo (range) | 32 (4-66) |
| Patients positive for Bcr-Abl KD mutations at the time of IM failure, n (%) | 51 (54) |
| Patients who received dasatinib as second TKI, n | 55 |
| Patients who received nilotinib as second TKI, n | 40 |
| Patients who received dasatinib as third TKI, n | 19 |
| Patients who received nilotinib as third TKI, n | 7 |
CML indicates chronic myeloid leukemia; CP, chronic phase; AP, accelerated phase; BC, blast crisis; Ph+ ALL, Philadelphia-positive acute lymphoblastic leukemia; IM, imatinib mesylate; KD, kinase domain; and TKI, tyrosine kinase inhibitor.